MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine

MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine

A special issue was published in the Journal of Personalized Medicine. Dr. Alessandra Pulliero from the University of Genoa in Italy talks about microRNA. Specifically, the role of microRNA in cancer development and personalized medicine. A microRNA (miRNA) is a small part of an RNA molecule. MiRNAs play a key role in the regulation of gene expression in cells, including mesothelioma cells. Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Asbestos also causes a progressive lung disease called asbestosis. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. Malignant mesothelioma is characterized by poor prognosis and short survival. Personalized Medicine and Mesothelioma Scientists now know that the role of miRNAs changes once they … Continue reading MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine »

New Drug Targeting Fibrosis may Help Mesothelioma Patients

Targeting Fibrosis in Mesothelioma has Therapeutic Benefits

Targeting fibrosis has therapeutic benefits in mesothelioma. Most drugs have limited effects in difficult-to-treat cancers such as mesothelioma. Often this is because not enough of the drug can get into the tumor to generate an anti-tumor effect. Fibrosis is a common element of mesothelioma. It causes the area around the cancer to stiffen. Fibrosis acts as a barrier, stopping drugs from getting into the cancer tumor. This limits the immune system’s ability to detect and access the tumor to kill it. A new study is looking at how a family of proteins called lysyl oxidases can help solve this problem. These proteins are associated with fibrosis in many cancers, including mesothelioma. Oncologists targeting fibrosis and this protein family may improve … Continue reading New Drug Targeting Fibrosis may Help Mesothelioma Patients »

Two New Diagnostic Tissue Biomarkers Discovered for Mesothelioma

Identifying Two New Diagnostic Tissue Biomarkers for Mesothelioma

Scientists have now identified two new diagnostic tissue biomarkers for malignant pleural mesothelioma. Doctors identify mesothelioma using diagnostic tissue biomarkers. This is called immunohistochemistry. The use of immunohistochemistry improves the accuracy of mesothelioma diagnosis in clinical practice. Yet, new methods for discovering diagnostic markers are still needed. Following a Reverse Approach in a Rare Case Mesothelioma is usually diagnosed after a person experiencing symptoms goes to a doctor. One thing a doctor may do is perform a tissue biopsy. The doctor will remove a part of the tissue (suspected mesothelioma) for examination. Most tissue biopsies are done with a needle and then examined in a laboratory. The lab will look for specific biomarkers to find out if the tissue contains … Continue reading Two New Diagnostic Tissue Biomarkers Discovered for Mesothelioma »

Detecting Mesothelioma by Smell: A Promising Future

Detecting Mesothelioma by Smell

Early cancer detection can be difficult, but there is a promising history of research on detecting mesothelioma by smell. A new study suggests that a change in a patient’s body odor may be used for early malignant pleural mesothelioma detection. This holds tremendous hope for early treatment. Right now, pleural mesothelioma detection relies heavily on various clinical tests. These tests often include radiography, CT, MRI, ultrasound, and biopsy. All of these technologies and methods are effective. However, several are invasive, expensive, time-consuming, or limited to large hospital settings. In an article in BBA – Reviews on Cancer, researchers explore how body odor can detect malignant pleural mesothelioma. The team says the research on detecting mesothelioma by smell is promising. Nevertheless, … Continue reading Detecting Mesothelioma by Smell: A Promising Future »

Cancer Biomarker Test Could Detect Mesothelioma Earlier

cancer biomarker test

A new cancer biomarker test that promises to identify cancer in patients with “non-specific symptoms” could be the key to detecting mesothelioma earlier.  Malignant mesothelioma is a deadly cancer caused by asbestos. The early symptoms of mesothelioma are usually vague and similar to other conditions. As a result, mesothelioma is frequently diagnosed in a late stage. But a cancer biomarker test developed in the UK could change that. The test looks for small molecules called metabolites in the blood. Its developers say it has the potential to find cancer earlier than other blood-based cancer tests.  Non-Specific Symptoms Make Mesothelioma a Diagnostic Challenge Mesothelioma is a rare cancer. It is most common in people who worked or lived around asbestos in … Continue reading Cancer Biomarker Test Could Detect Mesothelioma Earlier »

Patients Live Twice as Long with Less of this Biomarker for Pleural Mesothelioma

biomarker for pleural mesothelioma

An enzyme that helps mop up the products of cellular oxidation might also serve as a powerful biomarker for pleural mesothelioma. People with the lowest levels of this enzyme  survived longer with mesothelioma than those with higher levels. Glutathione peroxidase-1 (GPX-1) is an enzyme found in all cells. It helps keep toxins from building up inside cells. It also helps regulate certain cellular processes.   But there is also evidence that GPX-1 may play a role in the development of cancer. Researchers in Egypt recently discovered that pleural mesothelioma tumors have more GPX-1 than the healthy tissue around them. The less they have, the better the prognosis.  The findings suggest that GPX-1 could be a useful biomarker for pleural mesothelioma.  Mesothelioma … Continue reading Patients Live Twice as Long with Less of this Biomarker for Pleural Mesothelioma »

Blood Test May Reveal History of Exposure to Asbestos

exposure to asbestos

Small, non-coding bits of RNA in blood serum may offer a way to measure a person’s exposure to asbestos and predict their risk for mesothelioma.  Malignant mesothelioma is just one of several types of cancer linked to exposure to asbestos. But, unless a person knows they have been exposed, doctors might not even think to look for it, even when a patient develops early symptoms.  Researchers at Italy’s University of Ferrara have identified a microRNA in blood serum that can act as a biomarker for asbestos in the body. The discovery could lead to a blood test to identify high-risk people.  Exposure to Asbestos and Malignant Mesothelioma Before asbestos, mesothelioma was virtually unheard of. In fact, when the first asbestos-exposed … Continue reading Blood Test May Reveal History of Exposure to Asbestos »

Researchers Discover How Three Enzymes Influence Mesothelioma Risk

mesothelioma risk

University of Hawaii scientists have just released new research that helps explain how three enzymes may work together to determine mesothelioma risk. Most people who contract malignant mesothelioma have a history of asbestos exposure. But scientists still are not sure exactly why some people are at higher risk than others.  Researcher Michele Carbone and his team at the University of Hawaii Cancer Center have spent years trying to understand the underlying mechanism of mesothelioma risk. Their new report is a big step forward. It shows how three molecules interact to determine a person’s risk profile. It also demonstrates how something as simple as aspirin might be used to modify that risk.  Three Molecules That Influence Mesothelioma Risk BAP1 is a … Continue reading Researchers Discover How Three Enzymes Influence Mesothelioma Risk »

Could Lipids Hold the Key to Improving the Mesothelioma Diagnostic Process?

mesothelioma diagnostic process

A new Chinese report suggests that molecules called lipids could hold the key to improving the mesothelioma diagnostic process. Mesothelioma is rare and hard to treat. It is critical to diagnose it accurately and as early as possible for the best outcomes. But the mesothelioma diagnostic process can be complex and difficult.  The Chinese researchers compared the amounts and types of lipids in the blood of mesothelioma patients to those in the blood of healthy people. They discovered five lipids that were higher in the mesothelioma patients and 29 that were lower.  The information could help doctors refine the mesothelioma diagnostic process. It could also help them determine how a patient is doing on a particular treatment.  Lipids and the … Continue reading Could Lipids Hold the Key to Improving the Mesothelioma Diagnostic Process? »

Mesothelioma Blood Test Could Help Delay Time Between CT Scans

mesothelioma blood test

A mesothelioma blood test could make it possible to stretch the time between CT scans to monitor treatment progress. That is the conclusion from a team of cancer experts in Italy. The researchers compared the results of the SMRP mesothelioma blood test to CT scans and other prognostic indicators in pleural mesothelioma patients.  Doctors typically use a set of criteria called mRECIST to assess how well a particular therapy is working. mRECIST includes measurements from CT scans. But CT scans are expensive, time-consuming, and expose patients to ionizing radiation.  The goal of the new study was to see how closely SMRP levels correlated with mRECIST results. The team says the blood test appears to be accurate enough that it could … Continue reading Mesothelioma Blood Test Could Help Delay Time Between CT Scans »

Get your free copy of
“Surviving Mesothelioma” Today!